Bayer Aktiengesellschaft (BAYRY) Expected to Announce Earnings on Tuesday

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) is expected to be releasing its resultson Tuesday, May 12th. Analysts expect Bayer Aktiengesellschaft to post earnings of $0.64 per share and revenue of $15.7720 billion for the quarter. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings results on Wednesday, March 4th. The company reported $0.18 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.18. The company had revenue of $13.24 billion for the quarter, compared to analyst estimates of $13.08 billion. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.93%. On average, analysts expect Bayer Aktiengesellschaft to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bayer Aktiengesellschaft Stock Performance

OTCMKTS BAYRY traded up $0.22 during midday trading on Tuesday, hitting $11.05. The company had a trading volume of 936,144 shares, compared to its average volume of 1,239,743. The company has a quick ratio of 0.63, a current ratio of 1.01 and a debt-to-equity ratio of 1.22. The stock has a market cap of $43.41 billion, a price-to-earnings ratio of -9.95 and a beta of 0.62. The firm has a fifty day simple moving average of $11.46 and a two-hundred day simple moving average of $10.80. Bayer Aktiengesellschaft has a fifty-two week low of $6.20 and a fifty-two week high of $14.85.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. DZ Bank raised Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Thursday, April 9th. Zacks Research lowered shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 24th. Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Finally, UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Bayer Aktiengesellschaft presently has a consensus rating of “Moderate Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.